| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CDKN2A; CDKN2; MTS1; Cyclin-dependent kinase inhibitor 2A; isoforms 1/2/3; Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A |
| Entrez GeneID | 1029 |
| WB Predicted band size | Calculated MW: 17 kDa; Observed MW: 17 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Recombinant protein of human CDKN2A/p16INK4a |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于CDKN2A/p1616INK4a抗体的参考文献概览：
---
1. **"p16INK4a immunohistochemistry in cervical biopsies: multicenter assessment of accuracy and reproducibility"**
- **作者**: Galgano MT 等
- **摘要**: 该研究评估了不同实验室使用多种p16INK4a抗体(如克隆号E6H4)在宫颈活检组织中的免疫组化检测一致性与准确性，确认其在高级别鳞状上皮内病变(HSIL)诊断中的可靠性。
---
2. **"Comparative analysis of p16INK4a antibody clones in head and neck squamous cell carcinoma diagnostics"**
- **作者**: Lewis JS 等
- **摘要**: 对比了多种p16INK4a抗体(如克隆号JC8、G175-405)在头颈部鳞癌中的表达检测性能，发现克隆号JC8在高风险HPV相关肿瘤中特异性更高，强调抗体选择对诊断结果的影响。
---
3. **"p16INK4a as a prognostic marker in melanoma: validation by tissue microarray and antibody comparison"**
- **作者**: Elder DE 等
- **摘要**: 通过组织芯片技术验证了p16INK4a抗体(克隆号DCS-50.1)在黑色素瘤中的表达与预后的相关性，发现其缺失与肿瘤进展和不良预后显著相关。
---
4. **"Antibody validation for Western blot analysis of p16INK4a in pancreatic cancer cell lines"**
- **作者**: Yachida S 等
- **摘要**: 验证了多种p16INK4a抗体在Western blot中的特异性，确认克隆号F-12在胰腺癌细胞系中能稳定检测到因CDKN2A缺失导致的蛋白表达缺失。
---
这些文献覆盖了抗体在不同疾病模型、检测方法(免疫组化、Western blot)中的验证和应用，可为实验设计和抗体选择提供参考。
The CDKN2A gene encodes p16INK4a, a critical tumor suppressor protein that regulates cell cycle progression by inhibiting cyclin-dependent kinases (CDK4/CDK6), thereby preventing phosphorylation of the retinoblastoma (Rb) protein and blocking G1-to-S phase transition. Dysregulation of p16INK4a, through genetic mutations, deletions, or epigenetic silencing, is strongly associated with various cancers, including melanoma, pancreatic, and lung cancers. Conversely, its overexpression is linked to cellular senescence and aging.
Antibodies targeting p16INK4a are widely used in research and diagnostics to assess protein expression levels, particularly in cancer pathology. These antibodies are generated using immunogens derived from recombinant p16INK4a protein fragments or synthetic peptides, enabling detection via immunohistochemistry (IHC), Western blotting, or immunofluorescence. In clinical settings, p16INK4a IHC serves as a surrogate marker for high-risk human papillomavirus (HPV) infection in cervical and head/neck cancers, aiding in cancer risk stratification. It also helps differentiate benign lesions from dysplastic or malignant tissues.
Quality validation of p16INK4a antibodies is essential, as variability in specificity and sensitivity can impact diagnostic accuracy. Standardized protocols and antibody validation using knockout controls or known positive/negative samples are recommended. Its role as a prognostic biomarker and therapeutic target continues to drive interest in refining antibody-based applications for precision oncology.
×
